Neuland Laboratories share news and announcements
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Last close ₹18,865.00down ₹70.00 (0.37%)BSE ₹18,924.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹18,935.00.
52-week range of traded prices to 23 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹24,204 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 48.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 12.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 May 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 53,34748.3% delivered
Neuland Laboratories record dates, bonuses and splits
18 filed, newest first.
May 2025
15 May · Corporate action
May 2024
May 2023
Jun 2022
17 Jun · Corporate action
Jun 2021
Oct 2020
20 Oct · Corporate action
Jun 2020
Feb 2020
Dec 2017
Nov 2017
Nov 2014
8 Nov · Corporate action
Aug 2014
4 Aug · Corporate action
Company has fixed Record Date as August 14, 2014 for the purpose of Rights Issue.
Jun 2013
27 Jun · Corporate action
Company has fixed Book Closure from July 26, 2013 to August 2, 2013 for the purpose of dividend and Annual General Meeting of the Company to be held on August 02, 2013.
May 2012
7 May · Corporate action
Board of Directors in its meeting held on May 03, 2012, have fixed the book closure from August 07, 2012 to August 10, 2012 (both days inclusive) for the purpose of ensuing Annual General Meeting.
Mar 2012
Jul 2011
7 Jul · Corporate action
Board of Directors of the Company at its meeting held on July 07, 2011, inter alia, has accorded consent to a Rights Issue of Equity Shares not exceeding Rs. 12 crores. Further the Board at this meeting also constituted a Board Committee called the Rights Issue Committee to finalise the Rights ratio, issue price, record date and all other procedural modalities relating to the proposed Rights Issue.
May 2010
29 May · Corporate action
Board of Directors in its meeting held on May 29, 2010, have fixed the book closure from July 26, 2010 to July 29, 2010 (both days inclusive) for the purpose of ensuing Annual General Meeting pursuant to Section 154 of the Companies Act 1956 and the Listing Agreement.
May 2009
26 May · Corporate action
Neuland Laboratories Ltd had informed the Exchange regarding the book closure from July 15, 2009 to July 18, 2009 (both days inclusive) for the purpose of ensuing Annual General Meeting. The company has now informed the Exchange that this book closure period is for declaration of dividend purpose as well.